Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008;31(4):335-44.
doi: 10.2165/00002018-200831040-00007.

Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal

Affiliations
Randomized Controlled Trial

Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal

Maria T Herdeiro et al. Drug Saf. 2008.

Abstract

Background: Adverse drug reaction (ADR) reporting systems are the basic component for comprehensive postmarketing surveillance of the risk of drug-induced adverse effects. The aim of this study was to evaluate the effectiveness of educational outreach visits aimed at improving ADR reporting by pharmacists.

Methods: The study population comprised all pharmacists working in a catchment area covered by Portugal's Northern Regional Health Authority. Using unequal randomization, four spatial-clusters were assigned to the intervention group (n = 342) and eleven to the control group (n = 1091). The intervention took the form of 1-hour long educational outreach visits tailored to training needs detected in a previous study, with a 13- to 16-month follow-up period (March-June 2004 through June 2005). This study is registered as an international standard randomized controlled trial, number ISRCTN45894687.

Results: At baseline, ADR reporting rates (per 1000 pharmacist-years) did not differ significantly between the intervention and control groups (32.28 vs 29.16). The adjusted increase in ADR reporting attributable to the intervention was 275.63 per 1000 pharmacist-years (95% CI 162.15, 389.12; relative risk [RR] = 5.87, 95% CI 1.98, 17.39). The intervention succeeded in multiplying the reporting rate of: serious ADRs, 10-fold (RR = 9.79; 95% CI 2.24, 42.66); unexpected ADRs, 4-fold (RR = 4.41; 95% CI 1.11, 17.53); high-causality ADRs, 9-fold (RR = 8.67; 95% CI 2.12, 35.42); and new drug-related ADRs, 9-fold (RR = 9.33; 95% CI 2.53, 34.40). While the greatest effect was registered during the first 4 months post-intervention, differences remained statistically significant for 8 months.

Conclusions: Educational outreach visits improve ADR reporting by pharmacists in terms of quantity and relevance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. JAMA. 2006 Sep 6;296(9):1086-93 - PubMed
    1. Fam Pract. 2003 Apr;20(2):199-206 - PubMed
    1. BMJ. 1998 Apr 25;316(7140):1295-8 - PubMed
    1. Am J Health Syst Pharm. 2004 Jul 15;61(14):1466-72 - PubMed
    1. Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):429-34 - PubMed

Publication types

Associated data

LinkOut - more resources